the increase in
interest expenses between 2006 and 2007 at EUR 0.8 million. Meanwhile, a
more active management of our cash as well as an increased cash balance
over 2007 leads to higher financial gains in 2007 at EUR 1.3 million.
Nonetheless, the unfavourable evolution of the euro/dollars exchange rate
between the two year years has led to a currency rate loss of EUR 0.7
million during 2007, compared to a loss of EUR 0.3 million in 2006. As a
consequence, the financial result amounts to a loss of EUR 0.22 million in
2007 as compared to a gain of EUR 0.4 million in 2006.
The progression of our R&D expenses leads to an increase of the income
tax benefit from EUR 0.5 million in 2006 to EUR 0.7 million in 2007. On
December 31, 2007, the company had a Research Tax Credit receivable of EUR
As a consequence, ExonHit recorded a consolidated net loss of EUR 7.3
million in 2007 compared to EUR 4.5 million in 2006.
- Balance sheet
On December 31, 2007, the cash position of the Company amounted to EUR
31.3 million, against EUR 24.0 million at the end of 2006. As a result of a
number of share capital increases following the exercise of warrants and
stock-options and the issuance of new shares using the equity line with
Societe Generale convertible bonds, the Company strengthened its
- Cash flow statements
In 2007, ExonHit's net use of cash due to operating activities was EUR
4.9 million as compared to EUR 3.9 million for 2006. This difference is
mainly due to the increase of the loss from operations that is partly
balanced by a decrease in the "accounts receivables" line.
The capital expenditure to strengthen the SpliceArray(TM) business with
the opening of a new service laboratory in Paris mainly explains the
capital expenditure level of EUR 0.9 million in 2007, compared to EUR 0.3
million in 2006.
The financial operations generated EUR 13.3 million in 2007, this
compares with a generati
Page: 1 2 3 4 5 6 7 8 9 10 11 12 Related biology technology :1
|SOURCE ExonHit Therapeutics SA|
Copyright©2008 PR Newswire.
All rights reserved
. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials2
. ExonHit Completes a Prototype to Detect Alzheimers Disease From Blood3
. ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimers Disease4
. ExonHit and bioMerieux Amend Their Strategic Partnership5
. ExonHit Builds A New Organisation6
. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA7
. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review8
. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation9
. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway10
. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 200711
. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer